Bottom line
Is MRCGX a good fund? The bottom line
MRCGX is the Class C share class of Meridian Growth Fund, an actively managed large growth mutual fund from Meridian.
Its expense ratio is 2.01% — about $201 a year on every $10,000 invested, more expensive than 97% of large growth funds we track.
It returned −7.2% over one year, −2.3% a year over five years, +6.3% a year over ten (as of Dec 31, 2025, per its prospectus).
With $543 million in net assets and 91 holdings, its largest position is Stit Govt And Agency Inst (4.2%) and the top 10 make up 24.7% of the portfolio.
What stands out
- No front-end sales load
What to watch
- Expensive for its category (2.01%)
- 5-year return in the bottom quarter of its category
- 12b-1 marketing fee of 1% a year
Updated Nov 19, 2026
What MRCGX invests in
The M ERIDIAN G ROWTH F UND seeks long-term growth of capital.
The Fund attempts to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets, including the amount of any borrowings for investment purposes, in securities of growth companies. For purposes of the Funds 80% investment policy, a company is considered to be a growth company if it issues securities that are represented in a third-party growth-style index. The Fund may invest in companies that issue securities that are neither represented in any growth or value-style index (for example, a company that issues exclusively privately placed securities). The Fund may include such non-represented securities within the 80% test if the portfolio management team determines the company exhibits at least one growth characteristic similar to those commonly used by third-party index providers in growth classifications. Such characteristics may include…
From the fund's prospectus (filed Oct 30, 2026).
MRCGX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| MRCGX | −7.2% | −2.3% | +6.3% |
| Large Growth median | +15.2% | +11.0% | +14.2% |
Source: Fund prospectus, as of Dec 31, 2025
What MRCGX costs
On a $10,000 investment, MRCGX's 2.01% expense ratio costs about $201 a year. The prospectus estimates $2,064 in total costs over 10 years (assuming 5% annual returns). The median large growth fund charges 0.87%.
MRCGX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Stit Govt And Agency Inst | 4.17% |
| 2 | Rb Global Inc RBA | 2.49% |
| 3 | Curtiss-wright Corp CW | 2.46% |
| 4 | Axogen Inc AXGN | 2.43% |
| 5 | Federal Signal Corp FSS | 2.36% |
| 6 | Hinge Health Inc HNGE | 2.29% |
| 7 | Definium Therapeutics Inc DFTX | 2.20% |
| 8 | Veracyte Inc VCYT | 2.14% |
| 9 | Standardaero Inc SARO | 2.09% |
| 10 | Turning Point Brands Inc TPB | 2.08% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 24.7% of the fund. See all top 25 holdings and asset mix →